Platelet Aggregation is not Enhanced in Patients with Prediabetes

References

• Vmik A, Flemmer M (2002) Diabetes and macrovascular disease. J Diabetes Complications 16:235–245.
   PubMed Web of Science ®Google Scholar
• Can ME (2001) Diabetes mellitus: A hypercoagulable state. J Diabetes Complications 15:44–54.
   PubMed Web of Science ®Google Scholar
• Beckman JA, Creager M, Libby P (2002) Diabetes and atherosclerosis. Epidemiology, pathophysi-ology and management. JAMA 287:2570–2581.
   Google Scholar
• Plutzky J, Viberti G, Haffner SM (2002) Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. J Diabetes Complications 16:401–415.
   PubMed Web of Science ®Google Scholar
• Haffner SM (1997) Impaired glucose tolerance, insulin resistance and cardiovascular disease. Dia-bet Med 14:12–18.
   Web of Science ®Google Scholar
• Haffner SM, Mykkänen L, Festa A (2000) Insulin-resistant prediabetic subjects have more ather-ogenic risk factors than insulin-sensitive prediabetic subjects. Implications for preventing coro-nary heart disease during the prediabetic state. Circulation 101:975–980.
   Google Scholar
• Hu FB, Stampfer MJ, Haffner SM (2002) Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 25:1129–1134.
   PubMed Web of Science ®Google Scholar
• Garcia F, Calle LJ, Alava H (1987) Diabetes mellitus as a hypercoagulable state: its relationship with fibrin fragments and vascular damage. Thromb Res 47:533–540.
   PubMed Web of Science ®Google Scholar
• Dunn EJ, Grant PJ (2005) Type 2 diabetes: An atherothrombotic syndrome. Curr Mol Med 5:323–332.
   PubMed Web of Science ®Google Scholar
• Sagel J, Colwell JA, Crook L (1975) Increased platelet aggregation in early diabetes mellitus. Arm Intern Med 82:733–738.
   Google Scholar
• Report the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1998) Diabetes Care 21:5–19.
   Google Scholar
• Friedwald WT, Levy R, Fredrickson DS (1978) Estimation of serum low-density lipoprotein without the use of a preparative ultracentrifuge. Clin Chem 18:499–502.
   Google Scholar
• Wasunna A, Whitelaw A, Gallmore JR (1990) C-reactive protein and bacterial infection in pre-term infants. Eur J Pediatr 1449:424–427.
   Google Scholar
• Matthews DR, Hosker JP, Rudenski AS (1985) Homeostasis model assessment: insulin resist-ance and B-cell function from plasma glucose and insulin concentrations in man. Diabetologia 28:412–419.
   PubMed Web of Science ®Google Scholar
• Albareda M, Rodriguez-Espinosa J, Murugo M, de Leiva A, Corcoy R (2000) Assessment of insulin resistance and 13-cell function from measurements in the fasting states and during an oral glucose tolerance test. Diabetologia 43:1507–1511.
   PubMed Web of Science ®Google Scholar
• DECODE Study Group on behalf of the European Diabetes Epidemiology Group (2003) Is the current defmition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases. Diabetes Care 26:688–696.
   PubMed Web of Science ®Google Scholar
• Coutinho M, Gerstein HC, Wang Y (1999) The relationship between glucose and incident cardio-vascular events. A metaregression analysis of published data from 20 studies of 95,783 individu-als followed for 12.4 years. Diabetes Care 22:233–240.
   Google Scholar
• Levitan EB, Song Y, Ford ES (2004) Is nondiabetic hyperglycemia a risk factor for cardiovascu-lar disease? A meta-analysis of prospective studies. Arch Intern Med 164:2147–2155.
   PubMed Web of Science ®Google Scholar
• Haffner SM (2003) Pre-diabetes, insulin resistance, inflammation and CVD risk. Diabetes Res Clin Pract 61:9–18.
   PubMed Web of Science ®Google Scholar
• Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H, Erdem G, Gok M, Bingol N, Kilic S, Ozgurtas T, Bingol S (2007) Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 76:24–29.
   PubMed Web of Science ®Google Scholar
• Dogru T, Tasci I, Sonmez A, Genc H, Gok M, Yilmaz MI, Ural AU, Olgun A, Kilic S, Bozoglu E, Erdem G, Erbil K (2006) The plasma levels of soluble P-selectin in subjects with prediabetes. hit J Clin Pract 60:1048–1052.
   PubMed Web of Science ®Google Scholar
• Han TS, Sattar N, Williams K (2003) Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 26:1656–1657.
   Google Scholar
• Temelkova-Kurktschiev T, Siegert G, Bergmann S (2003) Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Curr Opin Lipidol 14:329–332.
   PubMed Web of Science ®Google Scholar
• Davi G, Gresele P, Violo F (1997) Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo-evidence derived from the study of peripheral arterial disease. Circulation 96:69–75.
   PubMed Web of Science ®Google Scholar
• Tasci I, Dogru T, Sonmez A, Genc H, Kilic S, Olgun A, Gok M, Erdem G, Erikci 5(2006) Soluble CD40 ligand levels in otherwise healthy subjects with impaired fasting glucose. Mediators of Inflamm 5:32508.
   Google Scholar
• Coban E, Bostan F, Ozdogan M (2006) The mean platelet volume in subjects with impaired fast-ing glucose. Platelets 17:67–69.
   Google Scholar
• Hekimsoy Z, Payzin B, Ornek T (2004) Mean platelet volume in Type 2 diabetic patients. J Dia-betes Complications 18:173–176.
   PubMed Web of Science ®Google Scholar
• Rosove MH, Frank HJ, Harwig SS (1984) Plasma beta-thromboglobulin, platelet factor 4, fibri-nopeptide A, and other haemostatic functions during improved, short-term glycemic control in diabetes mellitus. Diabetes Care 7:174–179.
   PubMed Web of Science ®Google Scholar
• Hughes A, McVerry BA, Wilkinson L (1983) Diabetes, a hypercoagulable state? Hemostatic vari-ables in newly diagnosed type 2 diabetic patients. Acta Haematol 69:254–259.
   Google Scholar
• Smith EB (1995) Fibrinogen, fibrin and the arterial wall. Eur Heart J 16:11–15.
   PubMed Web of Science ®Google Scholar
• Maresca G, Blasio AD, Marchioli R (1999) Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arterioscler Thromb Vasc Biol 19:1368–1377.
   PubMed Web of Science ®Google Scholar
• Fibrinogen Studies Collaboration (2004) Collaborative meta-analysis of prospective studies of plasma fibrinogen and cardiovascular disease. Eur J Cardiovasc Prey Rehabil 11:9–17.
   PubMedGoogle Scholar
• Richard L, Steven JH, Alicia JJ (2003) Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymor-phism in the DCCT/EDIC cohort. Diabetes Care 26:1439–1448.
   PubMed Web of Science ®Google Scholar
• Streja D, Cressey P, Rabkin SW (2006) Associations between inflammatory markers, traditional risk factors, and complications in patients with type 2 diabetes mellitus. J Diabetes Complications 17:120–127.
   Google Scholar